Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jill Lacy

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Cancer|June 25, 2025
Consensus guideline for the management of gastric cancer with synchronous peritoneal metastasesSamuel D Butensky, Varun V Bansal, David G Su, et al.
The Oncologist|March 20, 2023
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study PlatformAndrew H Ko, Kyu-Pyo Kim, Jens T Siveke, et al.
British Journal of Cancer|December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinomaMichael Cecchini, James M Cleary, Yu Shyr, et al.
Annals of Surgical Oncology|June 25, 2025
Consensus Guideline for the Management of Gastric Cancer with Synchronous Peritoneal MetastasesSamuel D Butensky, Varun V Bansal, David G Su, et al.
The Lancet. Gastroenterology & Hepatology|January 19, 2020
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A Philip, Jill Lacy, Fabienne Portales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2024
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 StudyPhilip A Philip, Vaibhav Sahai, Nathan Bahary, et al.
The Lancet. Oncology|May 11, 2016
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisMustafa Suker, Berend R Beumer, Eran Sadot, et al.
The Lancet. Oncology|February 6, 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic AdenocarcinomaEric Van Cutsem, Margaret A Tempero, Darren Sigal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO GuidelineManish A Shah, Erin B Kennedy, Ashley E Alarcon-Rozas, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Cancer|June 25, 2025
Consensus guideline for the management of gastric cancer with synchronous peritoneal metastasesSamuel D Butensky, Varun V Bansal, David G Su, et al.
The Oncologist|March 20, 2023
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study PlatformAndrew H Ko, Kyu-Pyo Kim, Jens T Siveke, et al.
British Journal of Cancer|December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinomaMichael Cecchini, James M Cleary, Yu Shyr, et al.
Annals of Surgical Oncology|June 25, 2025
Consensus Guideline for the Management of Gastric Cancer with Synchronous Peritoneal MetastasesSamuel D Butensky, Varun V Bansal, David G Su, et al.
The Lancet. Gastroenterology & Hepatology|January 19, 2020
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A Philip, Jill Lacy, Fabienne Portales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2024
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 StudyPhilip A Philip, Vaibhav Sahai, Nathan Bahary, et al.
The Lancet. Oncology|May 11, 2016
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisMustafa Suker, Berend R Beumer, Eran Sadot, et al.
The Lancet. Oncology|February 6, 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic AdenocarcinomaEric Van Cutsem, Margaret A Tempero, Darren Sigal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO GuidelineManish A Shah, Erin B Kennedy, Ashley E Alarcon-Rozas, et al.
Pageof 6